Linjardy M Xr (12.5mg/2.5mg/1000mg
Empagliflozin, linagliptin, and metformin XR for type 2 diabetes.
Linjardy M Xr (12.5mg/2.5mg/1000mg) combines empagliflozin (SGLT2), linagliptin (DPP-4), and metformin in extended-release formulation for type 2 diabetes when triple therapy is needed. Take once daily with meals as directed; swallow whole.
Purpose
Treatment of type 2 diabetes mellitus as adjunct to diet and exercise when triple therapy is appropriate.
Ingredients
Empagliflozin 12.5mg, linagliptin 2.5mg, and metformin hydrochloride 1000mg (extended-release) per tablet.
Warnings
Contraindicated in severe renal impairment and diabetic ketoacidosis. Not for type 1 diabetes. Risk of genital and urinary infections.
Side Effects
Nausea, diarrhoea, urinary tract infections, genital mycotic infections. Rare: ketoacidosis. Report unusual tiredness or abdominal pain.
Storage Instructions
Store below 30°C in a dry place. Keep in original pack; protect from moisture.
| Brand | CCL |
| Status | Active |
Related Products
